Viking Therapeutics announced positive topline results from the 33-week maintenance phase of VK2735. Mean weight loss reached 22% at week 33 with no evidence of plateau. VKTX stock did not rally on the data.
💡 Frequently Asked Questions (FAQ)
- Q: Why didn’t VKTX stock rally after the VK2735 22% weight loss results?
- A: The market may have already priced in strong efficacy, is waiting for Phase 3 confirmation, long-term safety data, or is comparing VK2735 to rival GLP-1 therapies with more advanced commercial timelines.
- Q: What is Viking Therapeutics VK2735?
- A: VK2735 is Viking Therapeutics’ investigational subcutaneous GLP-1/GIP dual agonist in development for chronic weight management and obesity.
- Q: Is 22% weight loss at week 33 with no plateau clinically significant?
- A: Yes. 22% mean weight loss is competitive with leading obesity drugs, and the absence of plateau through 33 weeks suggests durable efficacy during maintenance dosing.